Who is sponsoring NCT03295643?

NCT03295643 is sponsored by Jennifer Marler, MD.

What drugs are being tested in NCT03295643?

Interventions in NCT03295643: Mobile smoking cessation program and CO breath sensor device.

What condition does NCT03295643 study?

NCT03295643 studies Smoking Cessation.

Is NCT03295643 still recruiting?

NCT03295643 is currently completed. Last updated 1 July 2024.

Are results published for NCT03295643?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-07-01 · How we verify

NCT03295643

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Outcomes From a Mobile Smoking Cessation Program During a Monitoring Period of 6 Months

Completed NA Results posted Last updated 1 July 2024

What this trial tests

NA trial testing Mobile smoking cessation program and CO breath sensor device in Smoking Cessation in 319 participants. Completed in 30 November 2018.

Timeline

4 October 2017

Primary endpoint
31 July 2018

30 November 2018

Quick facts

Lead sponsor	Jennifer Marler, MD
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	319
Start date	4 October 2017
Primary completion	31 July 2018
Estimated completion	30 November 2018
Sites	1 location across United States

Drugs / interventions tested

Mobile smoking cessation program and CO breath sensor device

Conditions studied

Smoking Cessation — all drugs for Smoking Cessation →

Sponsor

Jennifer Marler, MD

Who can join

Adults 18 to 65, any sex, with Smoking Cessation. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants Who Completed the Explore Stage Primary · Assessment at the end of the Explore stage; 9 days after activating the app and device. Explore = 9 days. Build = 1 day to 4 weeks. Mobilize = 7 days.

For the number of participants who started the Explore Stage, the proportion who completed the Explore Stage.

Group	Value	95% CI
Mobile Smoking Cessation Program	283

Number of Participants Who Completed the Build Stage Primary · Assessment at the end of the Build stage; between 10 and 37 days after activating the app and device. Explore = 9 days. Build = 1 day to 4 weeks. Mobilize = 7 days.

For the number of participants who started the Build Stage, the proportion who completed the Build Stage.

Group	Value	95% CI
Mobile Smoking Cessation Program	183

Number of Participants Who Completed the Mobilize Stage Primary · Assessment at the end of the Mobilize stage; between 17 and 44 days after activating the app and device. Explore = 9 days. Build = 1 day to 4 weeks. Mobilize = 7 days.

For the number of participants who started the Mobilize Stage, the proportion who completed the Mobilize Stage.

Group	Value	95% CI
Mobile Smoking Cessation Program	139

Number of Participants Who Completed the Quit Stage Primary · Assessment at the end of the Quit Stage; between 24 and 51 days after activating the app and device. Explore = 9 days. Build = 1 day to 4 weeks. Mobilize = 7 days. Quit = 7 days.

For the number of participants who started the Quit Stage, the proportion who completed the Quit Stage.

Group	Value	95% CI
Mobile Smoking Cessation Program	131

Number of Participants Who Completed the Secure Stage Primary · Assessment at the end of the Secure Stage; between 101 and 128 days after activating the app and device. Explore = 9 days. Build = 1 day to 4 weeks. Mobilize = 7 days. Quit = 7 days. Secure = 11 weeks.

For the number of participants who started the Secure Stage, the proportion who completed the Secure Stage.

Group	Value	95% CI
Mobile Smoking Cessation Program	126

Readiness to Quit and Goals Related to Smoking Behavior Secondary · Assessment at the end of the Explore stage; 9 days after activating app and device. Explore = 9 days. Build = 1 day to 4 weeks. Mobilize = 7 days.

Are you seriously thinking of quitting smoking? (stage of change) "Yes, within the next 30 days". "Yes, within the next 6 months". "No, not thinking of quitting".

Baseline - Stage of Change

Group	Value	95% CI
Mobile Smoking Cessation Program	94
Mobile Smoking Cessation Program	176
Mobile Smoking Cessation Program	11

End of Explore Stage - Stage of Change

Group	Value	95% CI
Mobile Smoking Cessation Program	157
Mobile Smoking Cessation Program	114
Mobile Smoking Cessation Program	10

Average Percentage Change in Cigarettes Per Day (CPD) by the Pre-Quit Stage Secondary · Assessment at the end of the Mobilize stage; between 17 and 44 days after activating the app and device. Explore = 9 days. Build = 1 day to 4 weeks. Mobilize = 7 days.

Average percentage change in cigarettes per day (CPD) by the Pre-Quit Stage using repeated measures linear mixed model analysis. Model uses all available data on CPD to estimate an average. The Pre-Quit Stage is defined as from the start of the study (activation of the app and device/ Baseline) to the end of the Mobilize Stage.

Group	Value	95% CI
Mobile Smoking Cessation Program	-44.5	± 3

Weeks of Active Engagement Secondary · 6 months

Engagement defined as interaction with the program at least once within app (app open, daily check-in, responds to coach, logs cigarettes, etc) Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support. Mobile smoking cessation program and CO breath sensor device: Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.

Group	Value	95% CI
All Participants	12.4	± 7.1

Number of Participants Who Completed the Program Secondary · 6 months

The number of participants who completed the quit-smoking program.

Group	Value	95% CI
Mobile Smoking Cessation Program	272

Quit Attempts Secondary · 6 months

Number attempt to quit by participant

Group	Value	95% CI
Mobile Smoking Cessation Program	2.4	± 3.1

Quit Rate 7-day Point Prevalence Secondary · 6 months

Number of participant who have not smoked in last 7 days

Group	Value	95% CI
Mobile Smoking Cessation Program	102

Quit Rate 30-day Point Prevalence Secondary · 6 months

Number of participant who have not smoked in last 30 days

Group	Value	95% CI
Mobile Smoking Cessation Program	88

Sponsor's own description

Prospective, open label, single center clinical study enrolling 260 subjects in a mobile smoking cessation program using a smartphone app and a handheld breath sensor with coaching support over a six month period.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Initial Assessment of a Comprehensive Digital Smoking Cessation Program That Incorporates a Mobile App, Breath Sensor, and Coaching: Cohort Study.
Marler JD, Fujii CA, Utley DS, Tesfamariam LJ, et al · · 2019 · cited 32× · PMID 30670372 · DOI 10.2196/12609
Durability of Abstinence After Completing a Comprehensive Digital Smoking Cessation Program Incorporating a Mobile App, Breath Sensor, and Coaching: Cohort Study.
Marler JD, Fujii CA, Galanko JA, Balbierz DJ, et al · · 2021 · cited 17× · PMID 33482628 · DOI 10.2196/25578

Verify or expand the search:

Other recruiting trials for Smoking Cessation

Currently open trials in the same condition.

NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
NCT07224087 — Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients · Phase 1 · recruiting
NCT07331519 — Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer · NA · recruiting
NCT07210567 — Mindfulness-based Ecological Momentary Intervention for Smoking Cessation Among Cancer Survivors · NA · recruiting
NCT07129590 — Trauma-Informed Care for Smoking Cessation for Pregnancy · NA · recruiting

Other Jennifer Marler, MD trials

Trials by the same sponsor.

NCT04955639 — Pilot Randomized Controlled Trial of a Smart Phone-Based Smoking Cessation Program · NA · completed
NCT04133064 — Assessment of the Pivot Breath Sensor: Single-Arm Cohort Study · NA · completed
NCT03870022 — Pivot Breath Sensor Performance Study · NA · completed
NCT03835260 — Pivot Breath Sensor Human Factors and Usability Study · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03295643 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jennifer Marler, MD
Last refreshed: 1 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03295643.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing